 BOULDER, Colo., June 16, 2020 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it is scheduled to host a key opinion leaders KOL call regarding idiopathic pulmonary fibrosis IPF on Tuesday, June 23rd at 11 a.m. Eastern Time. The Company will also discuss encouraging new preclinical safety and efficacy data for its MRG-229 being developed for the treatment of IPF during the call. The call will feature a discussion by KOLs Fernando J. Martinez, MD, Weill Cornell Medicine, Teresa Barnes, Coalition for Pulmonary Fibrosis, and Naftali Kaminski, MD, Yale School of Medicine. 